Search Results - "Modak, Rucha V"

A Macrophage-Pericyte Axis Directs Tissue Restoration via Amphiregulin-Induced Transforming Growth Factor Beta Activation by Minutti, Carlos M., Modak, Rucha V., Macdonald, Felicity, Li, Fengqi, Smyth, Danielle J., Dorward, David A., Blair, Natalie, Husovsky, Connor, Muir, Andrew, Giampazolias, Evangelos, Dobie, Ross, Maizels, Rick M., Kendall, Timothy J., Griggs, David W., Kopf, Manfred, Henderson, Neil C., Zaiss, Dietmar M.

“…The epidermal growth factor receptor ligand Amphiregulin has a well-documented role in the restoration of tissue homeostasis after injury; however, the…”
Get full text

Magnetic Bead-Based Workflow for Sensitive and Streamlined Cell Surface Proteomics by Dieters-Castator, Dylan Z., Manzanillo, Paolo, Yang, Han-Yin, Modak, Rucha V., Rardin, Matthew J., Gibson, Bradford W.

“…Cell surface proteins represent an important class of molecules for therapeutic targeting and cellular phenotyping. However, their enrichment and detection via…”
Get full text

Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia by Modak, Rucha V, de Oliveira Rebola, Katia G, McClatchy, John, Mohammadhosseini, Mona, Damnernsawad, Alisa, Kurtz, Stephen E, Eide, Christopher A, Wu, Guanming, Laderas, Ted, Nechiporuk, Tamilla, Gritsenko, Marina A, Hansen, Joshua R, Hutchinson, Chelsea, Gosline, Sara J C, Piehowski, Paul, Bottomly, Daniel, Short, Nicholas, Rodland, Karin, McWeeney, Shannon K, Tyner, Jeffrey W, Agarwal, Anupriya

“…Emerging evidence underscores the critical role of extrinsic factors within the microenvironment in protecting leukemia cells from therapeutic interventions,…”
Get full text

Imidazolone as an Amide Bioisostere in the Development of β‑1,3‑N‑Acetylglucosaminyltransferase 2 (B3GNT2) Inhibitors by Jackson, Jeffrey J., Siegmund, Aaron C., Bai, Wen-Ju, Reed, Anthony B., Birkholz, Adam B., Campuzano, Iain D. G., Créquer-Grandhomme, Amandine, Hu, Ruozhen, Modak, Rucha V., Sudom, Athena, Javier, Noelle, Sanders, Christiana, Lo, Mei-Chu, Xie, Fang, Cee, Victor J., Manzanillo, Paolo, Allen, John G.

“…B3GNT2 is responsible for elongation of cell surface long-chain polylactosamine, which influences the regulation of the immune response, making it an…”
Get full text

Isolation and Culture of Murine Hepatic Stellate Cells by Modak, Rucha V, Zaiss, Dietmar M

“…Hepatic stellate cells (HSCs), alternatively known as liver pericytes, can differentiate into myofibroblasts and secrete extra-cellular matrix components,…”
Get full text

Abstract 5942: An integrated approach reveals novel extrinsic pathways and cytokine signatures associated with drug response in acute myeloid leukemia by Modak, Rucha V., Damnernsawad, Alisa, Laderas, Ted, Wu, Guanming, Tyner, Jeffery W., Rodland, Karin D., McWeeney, Shannon K., Agarwal, Anupriya

“…Abstract Background: Acute myeloid leukemia (AML) is a heterogeneous disease with a dismal 5 year survival rate below 30%. Current AML therapies have provided…”
Get full text

A Functional Profiling of Microenvironmental Factors and Small Molecules Reveals Monocyte Chemoattractant Protein-1 Mediates Drug Resistance in Acute Myeloid Leukemia by Modak, Rucha V, Gosline, Sara J, Damnernsawad, Alisa, Nechiporuk, Tamilla, Laderas, Ted, Wu, Guanming, Piehowski, Paul, Kurtz, Stephen E, Eide, Christopher A., Tyner, Jeffrey W., Rodland, Karin, McWeeney, Shannon K., Agarwal, Anupriya

“…Background: The treatment of acute myeloid leukemia (AML) patients is a formidable challenge, due to disease heterogeneity and the ability to acquire secondary…”
Get full text

Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML by Gosline, Sara J C, Tognon, Cristina, Nestor, Michael, Joshi, Sunil, Modak, Rucha, Damnernsawad, Alisa, Posso, Camilo, Moon, Jamie, Hansen, Joshua R, Hutchinson-Bunch, Chelsea, Pino, James C, Gritsenko, Marina A, Weitz, Karl K, Traer, Elie, Tyner, Jeffrey, Druker, Brian, Agarwal, Anupriya, Piehowski, Paul, McDermott, Jason E, Rodland, Karin

“…Acute Myeloid Leukemia (AML) affects 20,000 patients in the US annually with a five-year survival rate of approximately 25%. One reason for the low survival…”
Get full text